Professional
Added to YB: 2025-05-22
Pitch date: 2025-05-20
TRVI [bullish]
Trevi Therapeutics, Inc.
+97.03%
current return
Author Info
No bio for this author
Company Info
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Market Cap
$1.5B
Pitch Price
$6.40
Price Target
29.00 (+127%)
Dividend
N/A
EV/EBITDA
-24.85
P/E
-30.96
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Raymond James Reaffirms Strong Buy on TRVI, $29 PT Reiterated
TRVI: Raymond James $29 PT (reiterated Strong Buy). KOLs unveiled new Ph2a RIVER data for Haduvio in RCC: strongest efficacy signal to date per KOL, 'safe bet'. Central+peripheral MOA could expand beyond IPF-CC/RCC into other ILDs ('no-brainer'). New data includes awake cough frequency, dose response, LCQ QoL.
Read full article (1 min)